changes in HRT use since the publication of the replacement therapy were updated. Lines relating to the postmenopausal use of hormone advice to health professionals and women, and guide-report, government regulatory authorities issued replacement therapy (HRT) for the prevention of prevalence, frequent extensive media coverage came at a time when BMJ VOLUME 327 11 OCTOBER 2003 bmj.com

New Zealand observational study. We surveyed 998 duration oestrogen after menopause (WISDOM) and a women were screened from 23 general practices in Between January 2000 and November 2002, 3500 for the prevention of chronic diseases. In 2002 the Women’s Health Initiative reported the results of a study on the effects of combined oestrogen and progestogen on healthy postmenopausal women. They found increased rates of breast cancer, coronary heart disease, stroke, and venous thromboembolism and decreased rates of hip fracture and colorectal disease but no “global” benefit. They concluded that combined oestrogen and progestogen is not suitable for the prevention of chronic diseases.1 The subsequent extensive media coverage came at a time when the prevalence,2 duration,3 and use of hormone replacement therapy (HRT) for the prevention of chronic disease had been increasing.4 After the report, government regulatory authorities issued advice to health professionals and women, and guidelines relating to the postmenopausal use of hormone replacement therapy were updated.5 We examined changes in HRT use since the publication of the report.

Participants, methods, and results
Between January 2000 and November 2002, 3500 women were screened from 23 general practices in four New Zealand centres as part of the recruitment process for the women’s international study of long duration oestrogen after menopause (WISDOM) and a New Zealand observational study. We surveyed 998 women who were using HRT at the time they were screened but who were ineligible or unwilling to join the international study.

We sent participants an information sheet and questionnaire by post six months after the trial results were published. One reminder questionnaire was sent to non-responders, and 810 surveys (81%) were completed and returned. In total 776 respondents were taking HRT when the trial results were published and were eligible for inclusion. No significant differences were observed between non-responders (n = 188) and responders (n = 776) regarding age ($\chi^2 = 2.89, df = 3, P = 0.41$) and education ($\chi^2 = 1.78, df = 3, P = 0.62$). Non-responders were more likely than responders to have taken HRT for less than five years ($\chi^2 = 9.71, df = 2, P = 0.008$). The table shows the analyses for the 734 respondents for whom we had complete data on HRT use.

We analysed data using SAS Insight and estimated associations between a range of independent variables and the dependent variables (stopping and restarting HRT) from a generalised linear model with a log link and binomial errors. Independent variables included women’s age at the time of the survey, type of HRT, years of HRT use, hysterectomy status, education, and reasons for starting HRT.

Of the 734 respondents, 423 (58%) stopped taking HRT. Of the 423 who stopped when the results were published, 132 (18%) had restarted at the time of our survey and 291 (40%) had not. Most respondents (610, 83%) reported that they had discussed HRT with a
general practitioners, who are both qualified in maha-rishi vedic medicine, treat me as an equal, and we exchange views frankly and freely. I can take their advice on issues I raise, and they can suggest options without the slightest hint of offence if I decline. My use of maha-rishi ayurveda herbal preparations, lifestyle changes (diet, frequent swimming, etc), and regular meditation mean that I minimise the possibility of side effects and maximise my resistance to future problems. My only real criticism of this paper by Lewis and colleagues is that such a small number of women were interviewed. Based on my own experience, I would like to amplify some points from their research.

- True dialogue between patient and doctor is essential, and patients’ preference and values must be respected
- Patients want to make decisions to maximise their quality of life, and negotiated prescribing will yield better outcomes than imposed treatment
- Doctors will tend to have different values from patients, but the imbalance of power in the doctor-patient relationship causes them to have undue influence. To counter this, I would recommend that greater emphasis be placed on listening skills in doctor training and that more opportunities for “expert patient” training be provided on a routine basis
- People dislike unnecessary drug taking and would prefer lifestyle changes to “imperfect treatment.” (Is there such a thing as perfect treatment?) Unnecessary drug taking, which could include preventive treatment, can lead to the feeling of loss of control over health and reduce wellbeing, with subsequent negative impact on physical and mental health
- There is an urgent need to research those who decline treatment, and to provide alternative options including complementary therapies as required
- Finally, the cost of treatment is a huge issue. Cost is the biggest problem facing me, as I am living on a low income from incapacity benefit and income support. NHS treatments would be free, but herbal options and lifestyle choices cost money. Perhaps the NHS should fund well researched and patient friendly solutions such as transcendental meditation and maha-rishi ayurveda for those with chronic conditions.

Changes in use of hormone replacement therapy after the report from the Women’s Health Initiative: cross sectional survey of users
Beverley Lawton, Sally Rose, Deborah McLeod, Anthony Dowell

In 2002 the Women’s Health Initiative reported the results of a study on the effects of combined oestrogen plus progesterone on healthy postmenopausal women. They found increased rates of breast cancer, coronary heart disease, stroke, and venous thromboembolism and decreased rates of hip fracture and colorectal disease but no “global” benefit. They concluded that combined oestrogen and progesterone is not suitable for the prevention of chronic diseases.1 The subsequent extensive media coverage came at a time when the prevalence,2 duration,3 and use of hormone replacement therapy (HRT) for the prevention of chronic disease had been increasing.4 After the report, government regulatory authorities issued advice to health professionals and women, and guidelines relating to the postmenopausal use of hormone replacement therapy were updated.5 We examined changes in HRT use since the publication of the report.

Participants, methods, and results
Between January 2000 and November 2002, 3500 women were screened from 23 general practices in four New Zealand centres as part of the recruitment process for the women’s international study of long duration oestrogen after menopause (WISDOM) and a New Zealand observational study. We surveyed 998 women who were using HRT at the time they were screened but who were ineligible or unwilling to join the international study.

We sent participants an information sheet and questionnaire by post six months after the trial results were published. One reminder questionnaire was sent to non-responders, and 810 surveys (81%) were completed and returned. In total 776 respondents were taking HRT when the trial results were published and were eligible for inclusion. No significant differences were observed between non-responders (n = 188) and responders (n = 776) regarding age ($\chi^2 = 2.89, df = 3, P = 0.41$) and education ($\chi^2 = 1.78, df = 3, P = 0.62$). Non-responders were more likely than responders to have taken HRT for less than five years ($\chi^2 = 9.71, df = 2, P = 0.008$). The table shows the analyses for the 734 respondents for whom we had complete data on HRT use.

We analysed data using SAS Insight and estimated associations between a range of independent variables and the dependent variables (stopping and restarting HRT) from a generalised linear model with a log link and binomial errors. Independent variables included women’s age at the time of the survey, type of HRT, years of HRT use, hysterectomy status, education, and reasons for starting HRT.

Of the 734 respondents, 423 (58%) stopped taking HRT. Of the 423 who stopped when the results were published, 132 (18%) had restarted at the time of our survey and 291 (40%) had not. Most respondents (610, 83%) reported that they had discussed HRT with a
Factors associated with stopping hormone replacement therapy in six months after oestrogen and progestogen trial report

<table>
<thead>
<tr>
<th>Age at survey* (years)</th>
<th>Total No of women</th>
<th>Relative risk of stopping (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>49-54</td>
<td>68 (49)</td>
<td>134 Reference</td>
</tr>
<tr>
<td>55-59</td>
<td>137 (55)</td>
<td>249 1.13 (0.91 to 1.40)</td>
</tr>
<tr>
<td>60-64</td>
<td>121 (61)</td>
<td>197 1.32 (1.03 to 1.66)</td>
</tr>
<tr>
<td>≥65</td>
<td>99 (64)</td>
<td>154 1.42 (1.09 to 1.86)</td>
</tr>
</tbody>
</table>

Reasons for starting HRT:

- Symptom relief
  - 212 (55) 385 Reference
- Disease prevention
  - 171 (61) 279 1.16 (0.87 to 1.56)
- Other
  - 40 (57) 70 1.05 (0.78 to 1.40)

- Hysterectomy:
  - Yes 196 (55) 356 Reference
  - No 227 (60) 378 1.13 (0.95 to 1.33)

- Education level:
  - Non-tertiary 223 (59) 376 Reference
  - Tertiary 180 (56) 323 0.92 (0.77 to 1.09)
  - Other 14 (54) 26 0.88 (0.57 to 1.36)
  - Not known — 8

*Ostochrome-Armitage test for trend z=2.88, P=0.004 (for women who stopped).
†Oestrogen only-unopposed oestrogen preparations; combined HRT=continuous oestrogen and progestogen preparations; other=vaginal treatment, monthly bleed preparations.
‡Data collected at time of this survey, rather than at time of recruitment of women into the WISDOM trial.

We thank Selina Brown and the team of research nurses for their role in the collection of interview data from the cohort, for commenting on drafts of the questionnaire, and for assisting with sending the survey; Katie Abbott for entering questionnaire data on the database; Sonya White, who assisted with the questionnaire design; and the women for participating in this study.

Contributors: All authors developed the idea for the study and participated in the questionnaire design. SR drafted the questionnaire, reviewed the literature, and coordinated the survey. BL and SR wrote the introduction, SR and DM carried out the analysis and interpretation of the data and wrote the participants, method, and results sections. All authors edited and were responsible for the final version of the paper. BL will act as the guarantor.

Funding: The UK Medical Research Council (MRC) funded the recruitment of women into the WISDOM trial.

Competing interests: BL is a member of a New Zealand Guidelines committee focusing on the appropriate prescribing of hormone replacement therapy and has separately received conference and research grants from pharmaceutical companies. BL and AD were the principal investigators and SR a coinvestigator of WISDOM in New Zealand.

Ethical approval: The survey was approved by the Wellington Regional Ethics Committee, accredited by the Health Research Council of New Zealand.


(Accepted 18 September 2003)